Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › macrophage activation syndrome

Macrophage activation syndrome

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for macrophage activation syndrome

2 trials tracked for macrophage activation syndrome: 1 in phase 3 or 4.

2Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Phase 2 1
  1. Phase 3 Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE Completed
  2. Phase 2 A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH) Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of ruxolitinib for systemic juvenile arthritis with macrophage activation syndrome
Pediatrics Sys. Review
Review of ruxolitinib for systemic juvenile arthritis with macrophage activation syndrome Two children with severe arthritis found relief using a new drug approach
This narrative review synthesizes a retrospective case series and literature search on ruxolitinib for systemic juvenile idiopathic arthriti…
Two children with severe arthritis complications found relief using a new drug approach, offering hope for those who struggle with standard …
Frontiers May 28, 2026
Machine learning models predict macrophage activation syndrome risk in 737 patients with Still's disease
Allergy & Immunology Cohort
Machine learning models predict macrophage activation syndrome risk in 737 patients with Still's disease New Tool Predicts Dangerous Fever Flare
This multicenter, prospective observational study analyzed 737 patients with Still's disease to identify risk factors for macrophage activat…
A new tool predicts dangerous fever flares in Still's disease by spotting high-risk signs like age, ferritin levels, and inflammation marker…
Frontiers Apr 14, 2026